James Brian Windsor - 05 Mar 2024 Form 4 Insider Report for AILERON THERAPEUTICS INC (RNTX)

Role: President and COO
Signature: /s/ James Brian Windsor
Issuer symbol: RNTX
Transactions as of: 05 Mar 2024
Net transactions value: $0
Form type: 4
Filing time: 06 Mar 2024, 17:06:15 UTC
Previous filing: 18 Dec 2023
Next filing: 04 Dec 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALRN	Common Stock	Options Exercise		+2,000	+39%		7,122	05 Mar 2024	Direct	F1
holding	ALRN	Common Stock						225	05 Mar 2024	By son	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALRN	Series X Non-Voting Convertible Preferred	Options Exercise		-2	-100%		0	05 Mar 2024	Common Stock	2,000		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration.
F2	The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Content

On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration.

The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.